It is Poised to be a Bull Market for Verve Therapeutics Inc (VERV)

With 1.49 million shares changed hands, the volume of the stock remained heavier than its average volume of 1.33 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $6.83 whereas the lowest price it dropped to was $6.13. The 52-week range on VERV shows that it touched its highest point at $21.42 and its lowest point at $5.84 during that stretch. It currently has a 1-year price target of $26.89. Beta for the stock currently stands at 1.94.

Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of VERV was up-trending over the past week, with a rise of 1.14%, but this was down by -14.77% over a month. Three-month performance dropped to -48.89% while six-month performance fell -60.32%. The stock lost -64.46% in the past year, while it has lost -55.31% so far this year. A look at the trailing 12-month EPS for VERV yields -2.88 with Next year EPS estimates of -2.85. For the next quarter, that number is -0.66. This implies an EPS growth rate of 17.60% for this year and -10.82% for next year.

Float and Shares Shorts:

At present, 81.97 million VERV shares are outstanding with a float of 54.79 million shares on hand for trading. On 2024-04-30, short shares totaled 16.54 million, which was 1970.9998000000003 higher than short shares on 1711584000. In addition to Dr. Sekar Kathiresan M.D. as the firm’s Co-Founder, CEO & Director, Ms. Allison Dorval serves as its CFO & Principal Accounting Officer.

Institutional Ownership:

Through their ownership of 0.89527 of VERV’s outstanding shares, institutional investors have minority control over the company.

An Overview of Recent Financials:

Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-03-31, VERV reported revenue of $5695000.0 and operating income of -$56844000.0. The EBITDA in the recently reported quarter was -$55212000.0 and diluted EPS was -$0.59.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for VERV since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential.